Valneva SE (LON:0OB3)
3.784
+0.134 (3.67%)
At close: Feb 20, 2025
Valneva SE Employees
Valneva SE had 676 employees as of December 31, 2023. The number of employees decreased by 43 or -5.98% compared to the previous year.
Employees
676
Change (1Y)
-43
Growth (1Y)
-5.98%
Revenue / Employee
195.15K GBP
Profits / Employee
-9.13K GBP
Market Cap
497.77M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
AstraZeneca | 89,900 |
GSK plc | 70,212 |
Haleon | 25,408 |
Smith & Nephew | 18,452 |
Hikma Pharmaceuticals | 9,100 |
ConvaTec Group | 10,136 |
HUTCHMED (China) | 1,988 |
Oxford Nanopore Technologies | 1,238 |
Valneva SE News
- 5 days ago - Valneva Reports Preliminary Unaudited 2024 Revenue and Cash and Provides 2025 Outlook - GlobeNewsWire
- 18 days ago - Valneva rises after U.K. approval of chikungunya vaccine - Seeking Alpha
- 18 days ago - Valneva Receives Marketing Authorization in the UK for the World's First Chikungunya Vaccine, IXCHIQ® - GlobeNewsWire
- 24 days ago - Valneva wins new U.S. contract for Japanese encephalitis vaccine, Ixiaro - Seeking Alpha
- 24 days ago - Valneva Announces New IXIARO® Supply Contract with the U.S. Government Worth a Minimum of $32.8 Million - GlobeNewsWire
- 4 weeks ago - Valneva Is A 'Buy' As A First-Mover In Chikungunya - Seeking Alpha
- 4 weeks ago - Valneva Reports Positive Phase 2 Results in Children for its Chikungunya Vaccine and Announces Phase 3 Dose Decision - GlobeNewsWire
- 4 weeks ago - Valneva Vaccine Shows Sustained Immune Response In Adolescents One Year After Single Shot - Benzinga